Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Ingenovis Health acquisition of HealthCare Support Staffing
We are advising Cornell Capital, Trilantic Partners and Ingenovis Health on the transaction
Privia Health $174 million secondary offering
We advised Privia on its SEC-registered offering of stock
Alignment Healthcare $193 million SEC-registered secondary offering
The shares are listed on the Nasdaq Global Select Market
Novo Nordisk $3.3 billion acquisition of Dicerna Pharmaceuticals
We are advising Novo Nordisk on the transaction
BDT Capital Partners acquires a majority interest in MJH Life Sciences
We are advising BDT Capital Partners on the transaction
Apria $141.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market